Korean Journal of Clinical Oncology (대한종양외과학회지)

Korean Society of Surgical Oncology (대한종양외과학회)
권호 표지
DOI QR코드

DOI QR Code

Tissue factor expression is associated with recurrence in patients with non-metastatic colorectal cancer

  • Jung, Hee Jae (Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University) ;
  • Kim, Hye Jin (Department of Surgical Oncology, University of Tokyo Faculty of Medicine) ;
  • Kaneko, Kensuke (Department of Surgical Oncology, University of Tokyo Faculty of Medicine) ;
  • Kazama, Yoshihiro (Department of Surgical Oncology, University of Tokyo Faculty of Medicine) ;
  • Kawai, Kazushige (Department of Surgical Oncology, University of Tokyo Faculty of Medicine) ;
  • Ishihara, Soichiro (Department of Surgical Oncology, University of Tokyo Faculty of Medicine) ;
  • Choi, Gyu-Seog (Colorectal Cancer Center, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University)
  • Received : 2018.10.10
  • Accepted : 2018.12.20
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Previous studies have addressed the role of the hypercoagulable state in the pathogenesis of cancer progression and metastasis. In this study, we investigated the association between coagulation factors, including tissue factor (TF) expression, platelet count, and fibrinogen level, and disease recurrence in patients with non-metastatic colorectal cancer. Methods: Patients who underwent curative resection for stage II or III colorectal cancer between 2000 and 2007 were included in this study. Data from a prospectively maintained database were retrospectively reviewed. TF expression was determined by immunohistochemistry using an anti-TF monoclonal antibody. The Kaplan-Meier method was used to estimate 5-year disease-free survival. Results: TF was highly expressed in 257 of 297 patients (86.5%). TF expression was not significantly associated with the platelet counts (P=0.180) or fibrinogen level (P=0.281). The 5-year disease-free survival rate was lower in patients with high TF expression than in patients with low TF expression (72.3% vs. 83.9%, P=0.074). In Cox hazard analysis, high TF expression was an independent risk factor for tumor recurrence (hazard ratio [HR] 2.446; 95% confidence interval [CI], 1.054-5.674; P=0.037). Undifferentiated histologic type (HR, 2.911; 95% CI, 1.308-6.481; P=0.009), venous invasion (HR, 2.784; 95% CI, 1.431-5.417; P=0.003), and lymph node metastasis (HR, 2.497; 95% CI, 1.499-4.158; P<0.001), were also significantly associated with disease recurrence. Conclusion: TF expression is associated with a recurrence in patients with non-metastatic colorectal cancer. However, further studies are required to clarify the underlying mechanisms relating TF expression with oncologic outcomes and its potential role as a therapeutic target.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea

References

  1. Naina HV, Harris S. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:1840. https://doi.org/10.1056/NEJMc1203095
  2. Wang L, Huang X, Chen Y, Jin X, Li Q, Yi TN. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol 2012;38:568-73. https://doi.org/10.1016/j.ejso.2012.04.008
  3. Komurcuoglu B, Ulusoy S, Gayaf M, Guler A, Ozden E. Prognostic value of plasma D-dimer levels in lung carcinoma. Tumori 2011;97:743-8. https://doi.org/10.1177/030089161109700611
  4. Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012;36:192-200. https://doi.org/10.1007/s00268-011-1329-7
  5. Key NS, Geng JG, Bach RR. Tissue factor; from Morawitz to microparticles. Trans Am Clin Climatol Assoc 2007;118:165-73.
  6. Carmeliet P. Biomedicine: clotting factors build blood vessels. Science 2001;293:1602-4. https://doi.org/10.1126/science.1064981
  7. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-97.
  8. Koomagi R, Volm M. Tissue-factor expression in human nonsmall-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19-22. https://doi.org/10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.0.CO;2-Z
  9. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U
  10. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58S-68S. https://doi.org/10.1378/chest.124.3_suppl.58S
  11. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88-92. https://doi.org/10.1055/s-0037-1614634
  12. Akashi T, Furuya Y, Ohta S, Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003;62:1078-82. https://doi.org/10.1016/S0090-4295(03)00768-4
  13. Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006;24:755-61. https://doi.org/10.1200/JCO.2005.02.9181
  14. Khorana AA, Ahrendt SA, Ryan CK, Francis CW, Hruban RH, Hu YC, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-5. https://doi.org/10.1158/1078-0432.CCR-06-2351
  15. Yamashita H, Kitayama J, Taguri M, Nagawa H. Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg 2009;33:1298-305. https://doi.org/10.1007/s00268-009-9992-7
  16. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol 2010;102:428-32. https://doi.org/10.1002/jso.21668
  17. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice: the role of platelets in the spread of malignant disease. Int J Cancer 1973;11:704-18. https://doi.org/10.1002/ijc.2910110322
  18. Kawai K, Kitayama J, Tsuno NH, Sunami E, Nagawa H. Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis 2011;26:45-51. https://doi.org/10.1007/s00384-010-1054-y
  19. Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gomez H, Maffuz A, Rojas-Garcia P, et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res 2012;43:305-11. https://doi.org/10.1016/j.arcmed.2012.06.008
  20. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-7. https://doi.org/10.1172/JCI117451
  21. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105:1734-41. https://doi.org/10.1182/blood-2004-05-2042
  22. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-8. https://doi.org/10.1055/s-0037-1615384
  23. Chen L, Luo G, Tan Y, Wei J, Wu C, Zheng L, et al. Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient. Acta Histochem 2010;112:233-9. https://doi.org/10.1016/j.acthis.2008.11.024
  24. Nitori N, Ino Y, Nakanishi Y, Yamada T, Honda K, Yanagihara K, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-9. https://doi.org/10.1158/1078-0432.CCR-04-0866
  25. Rao B, Gao Y, Huang J, Gao X, Fu X, Huang M, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis 2011;26:593-601. https://doi.org/10.1007/s00384-011-1164-1
  26. Laterre PF, Wittebole X, Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost 2006;32:71-6. https://doi.org/10.1055/s-2006-933342
  27. Tenno T, Oberg F, Mackman N, Nilsson K, Siegbahn A. PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells. Thromb Haemost 2003;90:930-9. https://doi.org/10.1160/TH03-02-0087
  28. Ma Q, Tobu M, Schultz C, Jeske W, Hoppensteadt D, Walenga J, et al. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 2007;119:653-61. https://doi.org/10.1016/j.thromres.2006.05.007
  29. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000.
  30. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930-6. https://doi.org/10.1055/s-0037-1613114